New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges

• Published in: Cancers 2021-04, Vol.13 (8), p.1981
• Main Authors: Allegra, Alessandro, Pioggia, Giovanni, Innao, Vanessa, Musolino, Caterina, Gangemi, Sebastiano
• Format: Article
• Language: English
• Subjects: Apoptosis; Binding sites; Cancer; Cell cycle; Cell death; Cell growth; Cell proliferation; Cell survival; Chemoresistance; Chemotherapy; Connective tissue; DNA damage; Gene expression; Growth factors; Hematological diseases; Immunosurveillance; Kinases; Lymphoma; Mammals; Metabolism; Multiple myeloma; Neoplasia; Phosphorylation; Proteins; Review; Signal transduction; Transcription factors; Tumor cells; Tumorigenesis; Tumors; Yes-associated protein
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13081981

The Hippo/YES-associated protein (YAP) signaling pathway is a cell survival and proliferation-control system with its main activity that of regulating cell growth and organ volume. YAP operates as a transcriptional coactivator in regulating the onset, progression, and treatment response in numerous human tumors. Moreover, there is evidence suggesting the involvement of YAP in the control of the hematopoietic system, in physiological conditions rather than in hematological diseases. Nevertheless, several reports have proposed that the effects of YAP in tumor cells are cell-dependent and cell-type-determined, even if YAP usually interrelates with extracellular signaling to stimulate the onset and progression of tumors. In the present review, we report the most recent findings in the literature on the relationship between the YAP system and hematological neoplasms. Moreover, we evaluate the possible therapeutic use of the modulation of the YAP system in the treatment of malignancies. Given the effects of the YAP system in immunosurveillance, tumorigenesis, and chemoresistance, further studies on interactions between the YAP system and hematological malignancies will offer very relevant information for the targeting of these diseases employing YAP modifiers alone or in combination with chemotherapy drugs.